EARS Auris Medical Holding AG

0.64
-0.007  -1%
Previous Close 0.64
Open 0.65
Price To book 1.55
Market Cap 21.80M
Shares 34,329,000
Volume 265,328
Short Ratio 1.38
Av. Daily Volume 443,144

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Open label safety trial data released April 24, 2017 and May 9, 2017.
Keyzilen (AM-101) - AMPACT open-label
Acute inner ear tinnitus
Phase 3 HEALOS data due fall of 2017.
AM-111 HEALOS
Acute inner ear hearing loss
Phase 3 TACTT3 enrollment resumption announced January 26, 2017 with top-line results expected in early 2018.
Keyzilen (AM-101) - TACTT3
Acute inner ear tinnitus
Phase 3 ASSENT data due 2H 2018.
AM-111 ASSENT
Acute inner ear hearing loss
Phase 2 trial (REACH) enrollment pending funding.
AM-111 REACH
Surgery-induced hearing loss
Phase 3 trial did not meet primary endpoints
AM-101 (Keyzilen) - TACTT2
Acute inner ear tinnitus